公开(公告)号：US20180344829A1

公开(公告)日：2018-12-06

申请号：US15776452

申请日：2016-11-17

Applicant: INNATE PHARMA

Inventor： STEPHANIE CORNEN ,  LAURENT GAUTHIER ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: A61K39/00 ,  C07K14/705 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/2803 ,  C07K14/705 ,  C07K2317/33 ,  C07K2317/76 ,  C07K2319/30

Abstract: This disclosure relates to agents that bind and neutralize the inhibitory activity of Siglec-10 in lymphocytes, notably by inhibiting the binding of Siglec-10 to its sialic acid ligands on target cells, notably tumor cells. Such agents can be used for the treatment of cancers.

公开(公告)号：US20230235060A1

公开(公告)日：2023-07-27

申请号：US18164649

申请日：2023-02-06

Applicant: INNATE PHARMA

Inventor： PASCALE ANDRE ,  MATHIEU BLERY ,  CARINE PATUREL ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K39/395 ,  C07K16/30

CPC classification number: C07K16/2818 ,  C07K16/2803 ,  C07K16/2827 ,  A61K39/39558 ,  C07K16/30 ,  A61K2039/507

Abstract: The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

公开(公告)号：US20230085847A1

公开(公告)日：2023-03-23

申请号：US17933133

申请日：2022-09-19

Applicant: INNATE PHARMA

Inventor： STÉPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers.

公开(公告)号：US20210363249A1

公开(公告)日：2021-11-25

申请号：US17388059

申请日：2021-07-29

Applicant: INNATE PHARMA

Inventor： STEPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C12N5/12 ,  G01N33/574

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.

公开(公告)号：US20190085077A1

公开(公告)日：2019-03-21

申请号：US16082959

申请日：2017-03-07

Applicant: INNATE PHARMA

Inventor： STEPHANIE CORNEN ,  BENJAMIN ROSSI ,  NICOLAI WAGTMANN

IPC: C07K16/28 ,  A61P35/00 ,  G01N33/574 ,  C12N5/12 ,  A61K47/68

Abstract: This invention relates to agents that bind human Siglecs having inhibitory activity in immune cells, and that neutralize the inhibitory activity of such Siglec. Such agents can be used for the treatment of cancers or infectious disease.